BioVersys AG
Budget
€10 — €0
EP Access
0
accredited persons
Staff
2
0.2 FTE
EU Grants
€1,038,956
Mission & Goals
BioVersys AG is a Swiss biotech company, listed on the Swiss stock exchange (SIX: BIOV), researching and developing desperately needed medicines to fight anti-microbial resistance (AMR). BioVersys has two 100% owned subsidiaries, in Lille, France and Guangzhou, China. BioVersys has two products in clinical trials in addition to the research projects.
EU Legislative Interests
Focus is all Public Health related policies and legislations, for example related to pandemic preparedness and awareness e.g. anti-microbial resistance (AMR), HERA, EU Pharma Strategy
Communication Activities
See publications from the BEAM Alliance and EFPIA
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
BEAM Alliance (https://beam-alliance.eu/) Biotechnology Innovation Organization (USA) (https://www.bio.org/)
Additional Information
Estimated cost - we only listed our direct cost for the activities covered (ie membership, travel costs etc.). We do not spent much money for representation purposes, as we are a small biotech company
Commissioner Meetings
No recorded meetings with EU commissioners.